A Randomized, Parallel, Single-Center, Double-Masked, Vehicle-Controlled Phase II Study to Evaluate the Activity of NS2 Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Provocation Test (CAPT)

Trial Profile

A Randomized, Parallel, Single-Center, Double-Masked, Vehicle-Controlled Phase II Study to Evaluate the Activity of NS2 Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Provocation Test (CAPT)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Allergic conjunctivitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 07 Nov 2016 Results from this trial will be presented at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
    • 03 Mar 2016 According to an Aldeyra Therapeutics media release, additional data from this trial will be presented at the Cowen and Company 36th Annual Health Care Conference.
    • 29 Feb 2016 Primary endpoint 'Mean change from baseline in Ocular tearing scores' has been met, according to an Aldeyra media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top